Patient preferences for first-line treatment of classical Hodgkin lymphoma: a US survey and discrete choice experiment.

Leukemia & Lymphoma
Niloufer KhanMatthew Matasar

Abstract

A cross-sectional online survey, including a discrete choice experiment (DCE), was used to investigate first-line treatment preferences in patients with classical Hodgkin lymphoma (cHL) in the United States; 141 patients (median age 35.0 years) participated. In the DCE, risk of progression at 2 years (progression free survival) had the highest relative importance to patients (31.3%) when considering first-line treatments, followed by 2-year overall survival (OS; 26.9%), on-treatment pulmonary toxicity (23.3%), and on-treatment peripheral neuropathy (18.5%). Marginal rate of substitution analyses demonstrated that a 0.44% and 0.09% increase in 2-year OS was required for patients to accept a 1% increase in the risk of disease progression at 2 years and peripheral neuropathy, respectively. A 2.6% increase in 2-year OS was needed to accept a 7% rather than a 2% risk of pulmonary toxicity. In summary, patients with cHL rated survival attributes as more important than drug-related toxicity when considering first-line treatments.

References

Aug 15, 2001·Chest·S Sleijfer
Sep 28, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·William G MartinStephen M Ansell
Aug 26, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andreas EngertMarkus Löffler
Jan 29, 2010·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Axel C Mühlbacher, Matthias Nübling
Aug 25, 2010·Current Oncology Reports·Shrujal S Baxi, Matthew J Matasar
Jun 15, 2011·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·John F P BridgesJosephine Mauskopf
Nov 15, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Karolin BehringerPeter Borchmann
Jul 19, 2013·British Journal of Cancer·E W de Bekker-GrobE W Steyerberg
Jun 28, 2014·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Phaedra JohnsonDeborah A Marshall
Aug 6, 2014·Cancer·Laura J HavrileskyShelby D Reed
Aug 20, 2014·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Axel C Mühlbacher, Susanne Bethge
Nov 5, 2015·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·D StenehjemD Brixner
Dec 25, 2015·The New England Journal of Medicine·Michael SchaapveldFlora E van Leeuwen
Dec 30, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andreas Engert
Jun 23, 2016·The New England Journal of Medicine·Peter JohnsonSally Barrington
Jun 12, 2017·Gynecologic Oncology·UNKNOWN PEBC’s Ovarian Oncology Guidelines Group
Oct 21, 2017·Therapeutic Advances in Hematology·Liana NikolaenkoAlex F Herrera
Dec 12, 2017·The New England Journal of Medicine·Joseph M ConnorsUNKNOWN ECHELON-1 Study Group
Apr 11, 2018·American Journal of Hematology·Stephen M Ansell

❮ Previous
Next ❯

Citations

Jun 22, 2021·Frontiers in Public Health·Yue WangShuling Wang

❮ Previous
Next ❯

Related Concepts

Related Feeds

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.